Skip to content

Free cash flow at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.47B-56.6%
Stryker logo
StrykerSYK
$415M+227%
Novanta logo
NovantaNOVT
$47.47M+73.2%
PROCEPT BioRobotics Corporation logo
PROCEPT BioRobotics CorporationPRCT
-$41.04M-118%
Medtronic logo
MedtronicMDT
$2.09B+0.8%
IAR
Integra LifeSciencesIART
-$5.05M+87.4%

Other financials

Income statement

See full
Revenue$2.8B+23.0%
Gross profit$1.8B+25.6%
Operating income$855.3M+48.0%
Net income$821.5M+17.6%
EPS (diluted)$2.28+18.7%

Balance sheet

See full
Cash & equivalents$2.1B-21.6%
Total debt$170.9M+17.1%
Total equity$17.5B+2.2%
Total assets$20.1B+4.6%

Cash flow

See full
Operating cash flow$911.9M+56.8%
CapEx$103.3M-11.4%

Valuation

See full
Market cap$141.56B-22.5%
P/E47.5×-26.2×
P/S13.4×-7.6×

Profitability

See full
Gross margin66.3%-0.8pp
Operating margin30.5%+2.3pp
Net margin28.2%-0.3pp
FCF margin26.8%+6.8pp

Returns & leverage

See full
Return on equity17.2%+1.3pp
Debt / equity0.0×
Current ratio4.6×-0.4×

Where this comes from

Calculated from Intuitive Surgical’s reported figures.

The official record: Intuitive Surgical’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Intuitive Surgical's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Intuitive Surgical's free cash flow?
Intuitive Surgical (ISRG) reported free cash flow of $808.6M in Q1 2026.
How has Intuitive Surgical's free cash flow changed year-over-year?
Intuitive Surgical's free cash flow increased by 73.9% year-over-year, from $465M to $808.6M.
What is the long-term trend for Intuitive Surgical's free cash flow?
Over 3 years (2021 to 2025), Intuitive Surgical's free cash flow has grown at a 12.5% compound annual growth rate (CAGR), from $1.75B to $2.49B.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.